---
document_datetime: 2025-12-02 06:04:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lysodren.html
document_name: lysodren.html
version: success
processing_time: 0.1061202
conversion_datetime: 2025-12-28 04:36:02.206627
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lysodren

[RSS](/en/individual-human-medicine.xml/67001)

##### Authorised

This medicine is authorised for use in the European Union

mitotane Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lysodren](#news-on)
- [More information on Lysodren](#more-information-on-lysodren-1506)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Lysodren. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lysodren.

Expand section

Collapse section

## What is Lysodren?

Lysodren is a medicine that contains the active substance mitotane. It is available as tablets (500 mg).

## What is Lysodren used for?

Lysodren is used to treat the symptoms of advanced adrenal cortical carcinoma (cancer of the outer layer of the adrenal gland). It is used when the cancer is unresectable (cannot be removed by surgery), is metastatic (has spread to other parts of the body), or has relapsed (returned after treatment).

Because the number of patients with adrenal cortical carcinoma is low, the disease is considered 'rare', and Lysodren was designated an 'orphan medicine' (a medicine used in rare diseases) on 12 June 2002.

The medicine can only be obtained with a prescription.

## How is Lysodren used?

Treatment with Lysodren should be started and followed by a specialist who has suitable experience. The recommended starting dose in adults is 2 to 3 g per day, divided into two or three doses, taken with meals containing fatty food. A starting dose of 4 to 6 g per day can be used in patients who need urgent control of Cushing's syndrome (a set of symptoms of adrenal gland cancer caused by high hormone levels). The dose is increased in a stepwise manner until it reaches an 'optimal' dose that gives the best results without causing unacceptable side effects. The levels of the active substance in the blood should be monitored frequently, with the final target dose aiming to reach blood levels between 14 and 20 mg per litre. This is usually reached within three to five months. Levels above 20 mg/l may cause severe side effects without increasing the medicine's effectiveness.

The dose may be reduced or treatment interrupted if the patient experiences side effects. Treatment should continue as long as there is a benefit. If there is no improvement in symptoms after three months of treatment at the optimal dose, treatment should be stopped.

There is limited information on the use of Lysodren in children, but a daily starting dose of 1.5 to 3.5 g per square metre body surface area (calculated using the child's height and weight) is recommended.

Lysodren is not recommended for use in patients with severe liver or kidney problems, and it should be used with caution in those with mild or moderate liver or kidney problems. It should also be used with caution in elderly patients, with frequent monitoring of blood levels.

Patients who take Lysodren should receive the 'Lysodren patient card' that they should carry with them in case of emergency, to inform healthcare professionals (such as doctors and nurses) that they are taking the medicine.

## How does Lysodren work?

The cortex of the adrenal gland produces steroid hormones. When this area develops cancer, levels of these hormones can increase, causing the symptoms of the disease. The active substance in Lysodren, mitotane, is thought to work by preventing cells in the adrenal gland from working properly, by damaging their mitochondria (the energy-producing components), reducing the production of some steroid hormones. It may also alter the breakdown of these hormones. Together, these effects reduce the levels of the hormones in the body, improving the symptoms of the disease.

## How has Lysodren been studied?

Since the active substance in Lysodren, mitotane, is a well-established medicine that has been used in the treatment of adrenal cortical carcinoma in Europe since 1959, the company presented information from the published literature to support its application for Lysodren.

It presented the results of 220 studies published since 1990 on the use of the medicine in unresectable, metastatic adrenal cortical carcinoma. The studies included over 500 adults and children, who were treated for various lengths of time with mitotane, either alone or in combination with other anticancer medicines. The main measures of effectiveness in the studies included survival time, the reduction in tumour size and the time spent free of the symptoms of the disease.

## What benefit has Lysodren shown during the studies?

Overall, the studies suggested that Lysodren could provide a benefit in patients with advanced adrenal cortical carcinoma, by increasing survival times (by over five years in a few cases) and causing shrinkage or stabilisation of tumour size in 20 to 30% of patients. It also reduced the symptoms of the disease, particularly in patients whose cancer was producing high hormone levels. There was insufficient evidence to support its use as an add-on to other anticancer medicines. Limited information was available on the use of mitotane in children, but overall, the children remained disease free for an average of seven months when taking the medicine.

## What is the risk associated with Lysodren?

The most common side effects with Lysodren (seen in more than 1 patient in 10) are increased blood levels of liver enzymes, cholesterol and triglycerides (a type of fat), leucopenia (low white-blood-cell counts), prolonged bleeding time, ataxia (difficulty co-ordinating movements), paraesthesia (abnormal sensations like pins and needles), vertigo (a spinning sensation), sleepiness, mucositis (inflammation of the mucous membranes, such as the lining of the mouth), vomiting, diarrhoea, nausea (feeling sick), epigastric discomfort (discomfort around the stomach), skin rash, myasthenia (muscle weakness), adrenal insufficiency (reduced adrenal-gland activity), loss of appetite, asthenia (weakness), gynaecomastia (breast enlargement) and confusion. For the full list of all side effects reported with Lysodren, see the package leaflet.

Lysodren must not be used in people who are hypersensitive (allergic) to mitotane or any of the other ingredients. It must not be used in patients who are breast-feeding or who are taking spironolactone (a diuretic).

## Why has Lysodren been approved?

The CHMP decided that Lysodren's benefits are greater than its risks for the treatment of advanced adrenal cortical carcinoma, but noted that the effect of Lysodren has not been established in adrenal cortical carcinoma that is not producing high levels of steroid hormones. The Committee recommended that Lysodren be given marketing authorisation.

## Other information about Lysodren:

The European Commission granted a marketing authorisation valid throughout the European Union for Lysodren on 28 April 2004.

Lysodren : EPAR - Summary for the public

English (EN) (76.28 KB - PDF)

**First published:** 29/04/2009

**Last updated:** 18/07/2013

[View](/en/documents/overview/lysodren-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-316)

български (BG) (130.04 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/bg/documents/overview/lysodren-epar-summary-public_bg.pdf)

español (ES) (79.31 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/es/documents/overview/lysodren-epar-summary-public_es.pdf)

čeština (CS) (127.33 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/cs/documents/overview/lysodren-epar-summary-public_cs.pdf)

dansk (DA) (100.08 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/da/documents/overview/lysodren-epar-summary-public_da.pdf)

Deutsch (DE) (81.62 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/de/documents/overview/lysodren-epar-summary-public_de.pdf)

eesti keel (ET) (79.03 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/et/documents/overview/lysodren-epar-summary-public_et.pdf)

ελληνικά (EL) (129.85 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/el/documents/overview/lysodren-epar-summary-public_el.pdf)

français (FR) (101.74 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/fr/documents/overview/lysodren-epar-summary-public_fr.pdf)

italiano (IT) (102.42 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/it/documents/overview/lysodren-epar-summary-public_it.pdf)

latviešu valoda (LV) (124.05 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/lv/documents/overview/lysodren-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (103.61 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/lt/documents/overview/lysodren-epar-summary-public_lt.pdf)

magyar (HU) (123.61 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/hu/documents/overview/lysodren-epar-summary-public_hu.pdf)

Malti (MT) (108.19 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/mt/documents/overview/lysodren-epar-summary-public_mt.pdf)

Nederlands (NL) (80.29 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/nl/documents/overview/lysodren-epar-summary-public_nl.pdf)

polski (PL) (127.09 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/pl/documents/overview/lysodren-epar-summary-public_pl.pdf)

português (PT) (102.89 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/pt/documents/overview/lysodren-epar-summary-public_pt.pdf)

română (RO) (125.87 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/ro/documents/overview/lysodren-epar-summary-public_ro.pdf)

slovenčina (SK) (128.77 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/sk/documents/overview/lysodren-epar-summary-public_sk.pdf)

slovenščina (SL) (119.14 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/sl/documents/overview/lysodren-epar-summary-public_sl.pdf)

Suomi (FI) (85.41 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/fi/documents/overview/lysodren-epar-summary-public_fi.pdf)

svenska (SV) (101.94 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

18/07/2013

[View](/sv/documents/overview/lysodren-epar-summary-public_sv.pdf)

## Product information

Lysodren : EPAR - Product Information

English (EN) (530.88 KB - PDF)

**First published:** 29/04/2009

**Last updated:** 08/04/2025

[View](/en/documents/product-information/lysodren-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-486)

български (BG) (483.19 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/bg/documents/product-information/lysodren-epar-product-information_bg.pdf)

español (ES) (502.57 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/es/documents/product-information/lysodren-epar-product-information_es.pdf)

čeština (CS) (550.4 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/cs/documents/product-information/lysodren-epar-product-information_cs.pdf)

dansk (DA) (438.57 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/da/documents/product-information/lysodren-epar-product-information_da.pdf)

Deutsch (DE) (558.68 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/de/documents/product-information/lysodren-epar-product-information_de.pdf)

eesti keel (ET) (378.62 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/et/documents/product-information/lysodren-epar-product-information_et.pdf)

ελληνικά (EL) (488.64 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/el/documents/product-information/lysodren-epar-product-information_el.pdf)

français (FR) (433.26 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/fr/documents/product-information/lysodren-epar-product-information_fr.pdf)

hrvatski (HR) (452.83 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/hr/documents/product-information/lysodren-epar-product-information_hr.pdf)

íslenska (IS) (419.4 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/is/documents/product-information/lysodren-epar-product-information_is.pdf)

italiano (IT) (500.27 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/it/documents/product-information/lysodren-epar-product-information_it.pdf)

latviešu valoda (LV) (578.7 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/lv/documents/product-information/lysodren-epar-product-information_lv.pdf)

lietuvių kalba (LT) (426.67 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/lt/documents/product-information/lysodren-epar-product-information_lt.pdf)

magyar (HU) (469.74 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/hu/documents/product-information/lysodren-epar-product-information_hu.pdf)

Malti (MT) (480.13 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/mt/documents/product-information/lysodren-epar-product-information_mt.pdf)

Nederlands (NL) (541.62 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/nl/documents/product-information/lysodren-epar-product-information_nl.pdf)

norsk (NO) (476.48 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/no/documents/product-information/lysodren-epar-product-information_no.pdf)

polski (PL) (476.74 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/pl/documents/product-information/lysodren-epar-product-information_pl.pdf)

português (PT) (592.66 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/pt/documents/product-information/lysodren-epar-product-information_pt.pdf)

română (RO) (533.96 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/ro/documents/product-information/lysodren-epar-product-information_ro.pdf)

slovenčina (SK) (549.59 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/sk/documents/product-information/lysodren-epar-product-information_sk.pdf)

slovenščina (SL) (617.7 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/sl/documents/product-information/lysodren-epar-product-information_sl.pdf)

Suomi (FI) (382.05 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/fi/documents/product-information/lysodren-epar-product-information_fi.pdf)

svenska (SV) (400.76 KB - PDF)

**First published:**

29/04/2009

**Last updated:**

08/04/2025

[View](/sv/documents/product-information/lysodren-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0000248630 04/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lysodren : EPAR - All Authorised presentations

English (EN) (57.27 KB - PDF)

**First published:** 24/01/2006

**Last updated:** 24/01/2006

[View](/en/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_en.pdf)

[Other languages (18)](#file-language-dropdown-953)

español (ES) (56.72 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/es/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_es.pdf)

čeština (CS) (68.75 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/cs/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (58.06 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/da/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (60.46 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/de/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (55.78 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/et/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (77.65 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/el/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_el.pdf)

français (FR) (58.31 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/fr/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (55.32 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/it/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (77.32 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/lv/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (78.26 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/lt/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (68.6 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/hu/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_hu.pdf)

Nederlands (NL) (57.94 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/nl/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_nl.pdf)

polski (PL) (81.27 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/pl/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_pl.pdf)

português (PT) (58.85 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/pt/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_pt.pdf)

slovenčina (SK) (77.78 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/sk/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (78.16 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/sl/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (57.67 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/fi/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (58.54 KB - PDF)

**First published:**

24/01/2006

**Last updated:**

24/01/2006

[View](/sv/documents/all-authorised-presentations/lysodren-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lysodren Active substance mitotane International non-proprietary name (INN) or common name mitotane Therapeutic area (MeSH) Adrenal Cortex Neoplasms Anatomical therapeutic chemical (ATC) code L01XX23

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.

## Authorisation details

EMA product number EMEA/H/C/000521 Marketing authorisation holder

Esteve RD France SAS

25 Boulevard Romain Rolland 92120 Montrouge FRANCE

Marketing authorisation issued 28/04/2004 Revision 23

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lysodren : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (139.56 KB - PDF)

**First published:** 08/04/2025

[View](/en/documents/procedural-steps-after/lysodren-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Lysodren : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (140.03 KB - PDF)

**First published:** 29/04/2009

**Last updated:** 08/04/2025

[View](/en/documents/procedural-steps-after/lysodren-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Lysodren-H-C-521-PSUV-0016 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/34531/2015

English (EN) (67.26 KB - PDF)

**First published:** 04/05/2015

**Last updated:** 04/05/2015

[View](/en/documents/scientific-conclusion/lysodren-h-c-521-psuv-0016-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Lysodren-H-C-521-PSUSA-00002075-202004 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/30770/2021

English (EN) (95.68 KB - PDF)

**First published:** 04/05/2015

**Last updated:** 29/04/2021

[View](/en/documents/scientific-conclusion/lysodren-h-c-521-psusa-00002075-202004-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Lysodren-H-C-521-II-0014 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/419286/2013

English (EN) (825.53 KB - PDF)

**First published:** 18/07/2013

**Last updated:** 18/07/2013

[View](/en/documents/variation-report/lysodren-h-c-521-ii-0014-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Lysodren : EPAR - Scientific Discussion

English (EN) (460.16 KB - PDF)

**First published:** 24/01/2006

**Last updated:** 24/01/2006

[View](/en/documents/scientific-discussion/lysodren-epar-scientific-discussion_en.pdf)

Lysodren : EPAR - Procedural steps taken before authorisation

English (EN) (32.68 KB - PDF)

**First published:** 24/01/2006

**Last updated:** 24/01/2006

[View](/en/documents/procedural-steps/lysodren-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Lysodren

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2013) 31/05/2013

#### More information on Lysodren

Questions and answers on the outcome of an extension of indication application for Lysodren (mitotane)

Reference Number: EMA/323929/2013

English (EN) (73.92 KB - PDF)

**First published:** 31/05/2013

**Last updated:** 31/05/2013

[View](/en/documents/medicine-qa/questions-and-answers-outcome-extension-indication-application-lysodren-mitotane_en.pdf)

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu302102) on 12 June 2002. Lysodren was removed from the Community register of orphan medicinal products in April 2014 at the end of the 10-year period of market exclusivity.

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/04/2025

## Share this page

[Back to top](#main-content)